Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Mar;108(3):573–574. doi: 10.1111/j.1476-5381.1993.tb12843.x

Anti-inflammatory actions of an N-terminal peptide from human lipocortin 1.

G Cirino 1, C Cicala 1, L Sorrentino 1, G Ciliberto 1, G Arpaia 1, M Perretti 1, R J Flower 1
PMCID: PMC1908051  PMID: 8467352

Abstract

An acetylated polypeptide corresponding to residues 2-26 of human lipocortin 1 was synthesized and the anti-inflammatory activity assessed in three models of acute inflammation in rat and mouse. In the carrageenin rat paw oedema test, the peptide produced a maximal inhibition of approximately 41% at the 3 h time point with a 10 micrograms dose. When rat paw oedema was induced by the injection of venom phospholipase A2, the peptide produced a significant inhibition (31%) at the top dose of 20 micrograms per paw. In the mouse air-pouch model, systemic treatment with the peptide produced a dramatic reduction in cytokine-induced leukocyte migration with an ID50 of approximately 40 micrograms per mouse. The N-terminal peptide 2-26 shares the actions of lipocortin 1 in these acute models of inflammation.

Full text

PDF
573

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carey F., Forder R., Edge M. D., Greene A. R., Horan M. A., Strijbos P. J., Rothwell N. J. Lipocortin 1 fragment modifies pyrogenic actions of cytokines in rats. Am J Physiol. 1990 Aug;259(2 Pt 2):R266–R269. doi: 10.1152/ajpregu.1990.259.2.R266. [DOI] [PubMed] [Google Scholar]
  2. Chuah S. Y., Pallen C. J. Calcium-dependent and phosphorylation-stimulated proteolysis of lipocortin I by an endogenous A431 cell membrane protease. J Biol Chem. 1989 Dec 15;264(35):21160–21166. [PubMed] [Google Scholar]
  3. Cirino G., Flower R. J., Browning J. L., Sinclair L. K., Pepinsky R. B. Recombinant human lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung. Nature. 1987 Jul 16;328(6127):270–272. doi: 10.1038/328270a0. [DOI] [PubMed] [Google Scholar]
  4. Cirino G., Flower R. J. Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins. 1987 Jul;34(1):59–62. doi: 10.1016/0090-6980(87)90262-0. [DOI] [PubMed] [Google Scholar]
  5. Cirino G., Peers S. H., Flower R. J., Browning J. L., Pepinsky R. B. Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci U S A. 1989 May;86(9):3428–3432. doi: 10.1073/pnas.86.9.3428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goulding N. J., Luying P., Guyre P. M. Characteristics of lipocortin 1 binding to the surface of human peripheral blood leucocytes. Biochem Soc Trans. 1990 Dec;18(6):1237–1238. doi: 10.1042/bst0181237. [DOI] [PubMed] [Google Scholar]
  7. Notsu Y., Namiuchi S., Hattori T., Matsuda K., Hirata F. Inhibition of phospholipases by Met-Leu-Phe-Ile-Leu-Ile-Lys-Arg-Ser-Arg-His-Phe, C terminus of middle-sized tumor antigen. Arch Biochem Biophys. 1985 Jan;236(1):195–204. doi: 10.1016/0003-9861(85)90619-8. [DOI] [PubMed] [Google Scholar]
  8. Relton J. K., Strijbos P. J., O'Shaughnessy C. T., Carey F., Forder R. A., Tilders F. J., Rothwell N. J. Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain. J Exp Med. 1991 Aug 1;174(2):305–310. doi: 10.1084/jem.174.2.305. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES